Center for Genomic Medicine, Department of Medicine, Massachusetts General Hospital, 185 Cambridge Street, Simches Research Building | CPZN 6.256, Boston, MA, 02114, USA.
Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
BMC Med Genomics. 2021 Oct 1;14(1):238. doi: 10.1186/s12920-021-01056-0.
Polygenic scores-which quantify inherited risk by integrating information from many common sites of DNA variation-may enable a tailored approach to clinical medicine. However, alongside considerable enthusiasm, we and others have highlighted a lack of standardized approaches for score disclosure. Here, we review the landscape of polygenic score reporting and describe a generalizable approach for development of a polygenic score disclosure tool for coronary artery disease.
We assembled a working group of clinicians, geneticists, data visualization specialists, and software developers. The group reviewed existing polygenic score reports and then designed a two-page mock report for coronary artery disease. We then conducted a qualitative user-experience study with this report using an interview guide focused on comprehension, experience, and attitudes. Interviews were transcribed and analyzed for themes identification to inform report revision.
Review of nine existing polygenic score reports from commercial and academic groups demonstrated significant heterogeneity, reinforcing the need for additional efforts to study and standardize score disclosure. Using a newly developed mock score report, we conducted interviews with ten adult individuals (50% females, 70% without prior genetic testing experience, age range 20-70 years) recruited via an online platform. We identified three themes from interviews: (1) visual elements, such as color and simple graphics, enable participants to interpret, relate to, and contextualize their polygenic score, (2) word-based descriptions of risk and polygenic scores presented as percentiles were the best recognized and understood, (3) participants had varying levels of interest in understanding complex genomic information and therefore would benefit from additional resources that can adapt to their individual needs in real time. In response to user feedback, colors used for communicating risk were modified to minimize unintended color associations and odds ratios were removed. All 10 participants expressed interest in receiving a polygenic score report based on their personal genomic information.
Our findings describe a generalizable approach to develop a polygenic score report understandable by potential patients. Although additional studies are needed across a wider spectrum of patient populations, these results are likely to inform ongoing efforts related to polygenic score disclosure within clinical practice.
多基因评分-通过整合来自许多常见 DNA 变异位点的信息来量化遗传风险-可能使临床实践能够采用个性化的方法。然而,除了极大的热情之外,我们和其他人还强调缺乏标准化的评分披露方法。在这里,我们回顾了多基因评分报告的现状,并描述了一种可推广的方法,用于开发用于冠心病的多基因评分披露工具。
我们组建了一个由临床医生、遗传学家、数据可视化专家和软件开发人员组成的工作组。该小组审查了现有的多基因评分报告,然后为冠心病设计了两页模拟报告。然后,我们使用以理解、经验和态度为重点的访谈指南,对该报告进行了定性的用户体验研究。访谈记录被转录并进行主题识别分析,以提供报告修订的信息。
对来自商业和学术团体的九份现有多基因评分报告的审查表明存在显著的异质性,这加强了进一步努力研究和标准化评分披露的必要性。使用新开发的模拟评分报告,我们通过在线平台招募了 10 名成年参与者(50%为女性,70%没有遗传测试经验,年龄在 20-70 岁之间)进行了访谈。我们从访谈中确定了三个主题:(1)颜色和简单的图形等视觉元素可帮助参与者解释、关联和理解他们的多基因评分,(2)以风险和多基因评分的百分比表示的基于单词的描述是最容易识别和理解的,(3)参与者对理解复杂基因组信息的兴趣程度不同,因此他们将受益于可以实时适应其个人需求的其他资源。根据用户反馈,用于传达风险的颜色进行了修改,以尽量减少意外的颜色关联,并删除了比值比。所有 10 名参与者都表示有兴趣根据他们的个人基因组信息收到一份多基因评分报告。
我们的研究结果描述了一种可推广的方法,可用于开发潜在患者可理解的多基因评分报告。尽管还需要在更广泛的患者人群中进行更多研究,但这些结果可能会为正在进行的与临床实践中多基因评分披露相关的努力提供信息。